Related Experiment Video
Updated: Sep 10, 2025

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
Published on: September 20, 2016
Cryo-EM structures of human OAT1 reveal drug binding and inhibition mechanisms
Hyung-Min Jeon1, Jisung Eun1, Kelly H Kim2
1Department of Life Sciences, Pohang University of Science and Technology (POSTECH), Pohang 37673, Republic of Korea.
Abstract:
The organic anion transporter 1 (OAT1) plays a key role in excreting waste from organic drug metabolism and contributes significantly to drug-drug interactions and drug disposition. However, the structural basis of specific substrate and inhibitor transport by human OAT1 (hOAT1) has remained elusive. We determined four cryogenic electron microscopy (cryo-EM) structures of hOAT1 in its inward-facing conformation: the apo form, the substrate (olmesartan)-bound form with different anions, and the inhibitor (probenecid)-bound form. Structural and functional analyses revealed that Ser203 has an auxiliary role in chloride coordination, and it is a critical residue modulating olmesartan transport via chloride ion interactions. Structural comparisons indicate that inhibitors not only compete with substrates, but also obstruct substrate exit and entry from the cytoplasmic side, thereby increasing inhibitor retention. The findings can support drug development by providing insights into substrate recognition and the mechanism by which inhibitors arrest the OAT1 transport cycle.
Insights
Structural insights into human organic anion transporter 1 (hOAT1) reveal how substrates like olmesartan and inhibitors like probenecid bind. This clarifies transport mechanisms and potential drug interactions.
Area of Science:
- Biochemistry
- Structural Biology
- Pharmacology
Background:
- Organic anion transporter 1 (OAT1) is crucial for drug metabolism and disposition.
- Understanding OAT1's structure is key to predicting drug-drug interactions.
Purpose of the Study:
- Elucidate the structural basis of substrate and inhibitor transport by human OAT1 (hOAT1).
- Investigate the role of specific residues and ions in hOAT1 function.
Main Methods:
- Determined four cryogenic electron microscopy (cryo-EM) structures of hOAT1.
- Analyzed apo, substrate-bound (olmesartan), and inhibitor-bound (probenecid) forms.
Main Results:
- Identified Ser203's role in chloride coordination and olmesartan transport.
- Showed inhibitors block substrate entry/exit, increasing retention.
- Revealed structural differences between substrate and inhibitor binding.
Conclusions:
- OAT1 structure provides insights into substrate recognition and inhibitor mechanisms.
- Findings aid in developing drugs with fewer interactions and better disposition.
- Chloride ions play a key role in OAT1-mediated transport.
More Related Videos
09:30Author Spotlight: Exploring Cellular Processes by Modeling Ligands in Cryo-EM Maps
Published on: July 19, 2024
18:45Harvesting and Cryo-cooling Crystals of Membrane Proteins Grown in Lipidic Mesophases for Structure Determination by Macromolecular Crystallography
Published on: September 2, 2012
Related Concept Videos
Cryo-electron Microscopy
Protein-Drug Binding: Mechanism and Kinetics
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Gene Families
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Drug Binding to Blood Components
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...